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Antidepressant medication is commonly used for the prevention of depression recurrence in
the perinatal period, yet it is unknown what vulnerability markers may play a role in recur-
rence. The objective of the current study was to provide a descriptive overview of the associ-
ated characteristics of women who experienced a perinatal recurrence of depression
despite ongoing antidepressant use, and further, to identify clinically measurable vulnerabil-
ity markers associated with recurrence.
Methods
Eighty-five pregnant women with a history of depression who used antidepressants
(e.g. Selective Serotonin Reuptake Inhibitors or Serotonin and Noradrenaline Reup-
take Inhibitors) at the start of the study were included. Clinical features, including infor-
mation on psychiatric history and antidepressant use, were collected throughout the
perinatal period (in this study defined as the period between 12 weeks of pregnancy
untill three months postpartum). The clinical features of women experiencing recur-
rence of depression were described in detail. To identify vulnerability markers associ-
ated with recurrence of depression, we performed exploratory univariable logistic
regression analyses.
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Results
Eight women (9.4%) experienced a recurrence of depression; two during pregnancy and six
in the first 12 weeks postpartum. All women with recurrence of depression had first onset of
depression during childhood or adolescence and had at least 2 psychiatric co-morbidities.
Identification of vulnerability markers associated with recurrence of depression yielded
associations with depressive symptoms around 16 weeks of pregnancy (OR 1.28, 95%CI
1.08–1.52), number of psychiatric co-morbidities (OR 1.89, 95%CI 1.16–3.09) and duration
of antidepressant use (OR 1.01, 95%CI 1.00–1.02).
Conclusion
Implementing adequate risk assessment in pregnant women who use antidepressants can
help identify predictors for recurrence of depression in future studies and thus ultimately
lead to improved care.
Introduction
Mental illness during the perinatal period (i.e. during pregnancy up to three months postpar-
tum) is a common health problem [1], with approximately 25% of women experiencing any
psychiatric disorder in this period [2]. Perinatal depressive disorder is most common, with a
recent meta-analysis observing a pooled prevalence of 11.9% [3]. Untreated perinatal depres-
sion is not only unfavourable for the mother; it is also associated with adverse outcomes in the
offspring [4]. Exposure to antenatal depressive disorder is associated with increased risks of
premature delivery, low birth weight [5–7], and behavioural, emotional, cognitive and motor
problems in early childhood [8–10]. Ante- and postnatal depression can furthermore influence
the mother-infant relationship, posing increased risks for poor infant development [11–13].
Prevention or treatment of perinatal depression is therefore of importance. Several treat-
ment options are available [14], but international guidelines differ in their recommendations
[15] and clinicians are frequently noncompliant [16]. Antidepressant medication is an increas-
ingly used treatment option, either for prevention of recurrence of depression or as acute treat-
ment in newly depressed patients [17–19]. Perinatal prescription rates of antidepressants vary
per study setting and range from 2.1% to 13.4% [17, 19–21].
The preventive effect of continued antidepressant use in recovered women during the peri-
natal period remains unclear. A systematic review assessing the effectiveness of antidepressants
for prevention of postnatal depression, based on observational studies, could not draw any
clear conclusions due to low statistical power [22]. Two studies with a prospective naturalistic
design followed women who continued or tapered antidepressants, from their first trimester
throughout their pregnancy [23, 24]. One study showed an increased risk of recurrence in
women who discontinued their medication compared to women who continued their medica-
tion (68% vs. 26%) [23], the other study observed similar recurrence rates in women continu-
ing or discontinuing antidepressants (16% in total) [24]. A large retrospective administrative
data study comparing women who continued antidepressants during pregnancy to those who
discontinued showed women who continued were twice as likely (OR 2.0, 95%CI 1.8–2.2) to
have a depression inpatient stay [25].
From a clinical perspective, recognizing which pregnant women using antidepressants are
at risk for recurrence is vital. With this knowledge, clinicians could more accurately identify
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and inform patients, and subsequently arrange additional guidance when necessary. Collec-
tively these efforts could help promote the use of individualized patient-centred care, and
potentially prevent negative effects in the offspring. The purpose of the current study was to
describe cases with perinatal recurrence of depression out of a group of pregnant women
using antidepressants in their first trimester in detail. Clinical features of the women with
recurrence were inspected and reported. Additionally, vulnerability markers associated with
recurrence that are easily collected during routine care, were explored.
Methods
Setting and population
The present study is an observational study of 85 pregnant women that used antidepressants at
the start of the study and had a history of depression. This study was part of a larger nation-
wide research project on antidepressants, including both a randomized controlled trial (RCT),
called ‘Stop or Go’, in which women are randomized to continue or discontinue antidepres-
sants during pregnancy [26] and an observational cohort. The present manuscript does not
report on women from the RCT. The Medical Ethical Committee of the Erasmus Medical Cen-
ter approved both the RCT and observational cohort (MEC-2014-505).
Women were recruited for both studies during their prenatal booking visit in midwifery
practices and hospitals, through general practitioners, or through advertisement in (social)
media. When a potential eligible woman was identified, study researchers gave counselling
about the RCT and observational cohort. When women were unwilling or not eligible to par-
ticipate in the RCT, they were counseled for the observational cohort. Written informed con-
sent was necessary for participation.
For the present observational study, participants were considered eligible if they 1) were
between 12 and 16 weeks pregnant, 2) used a Selective Serotonin Reuptake Inhibitor (SSRI),
Selective Serotonin and Noradrenalin Reuptake Inhibitor (SNRI) or Tricyclic Antidepressant
(TCA), 3) had a history of at least one depressive episode as assessed by the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) [27], and 4) did not have a current diagnosis
of depression according to the SCID-I. Women without sufficient proficiency in Dutch or
English were excluded. No intervention was given in the observational cohort and participants
were free to decide themselves whether to continue or taper their antidepressants during study
follow-up. Participants were recruited between April 2015 and February 2018.
Perinatal recurrence of depression
We assessed relapse and recurrence, as defined by the SCID-I, during pregnancy and up to 12
weeks postpartum. Relapse is defined as the re-emergence of depressive symptoms during the
remission phase (being symptom-free from illness), but before full recovery (the absence of
symptoms for at least 4 months following the onset of remission). Recurrence is defined as the
onset of a new depressive episode during the recovery phase or long remission phase. We use
the word recurrence for further reference to both relapse and recurrence. The SCID-I was
assessed before 16 weeks of pregnancy (baseline assessment) and around 12 weeks
postpartum.
Clinical features of women with recurrence of depression
Clinical features, including information on psychiatric history and antidepressant use, were
documented. SCID-I DSM-IV diagnoses, age of first and last onset of depression (SCID-I),
number of depressive episodes (SCID-I), history of psychiatric hospital admission, psychiatric
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family history, antidepressant prescriber, current antidepressant dosage and number of previ-
ous discontinuation attempts were all determined around 16 weeks of pregnancy (baseline
assessment).
The Edinburgh Postnatal Depression Scale (EPDS) was administered at baseline, 24 and 36
weeks of pregnancy, and 4 and 12 weeks postpartum for the assessment of depressive symp-
toms [28, 29]. The Beliefs about Medicine Questionnaire, specific version (BMQ-s) was
administered at baseline [30]. The BMQ-s consists of two scales assessing 1) personal beliefs
about the necessity of prescribed medication for controlling one’s illness (score range 5–25)
and 2) concerns about the potential adverse consequences of taking medication (score range
6–30). Higher scores indicate stronger beliefs in the concepts of the scale. During follow-up,
data on healthcare use was collected using the Trimbos/iMTA questionnaire for Costs associ-
ated with Psychiatric Illness (TIC-P) for number of visits to the general practitioner (GP), psy-
chiatrist, psychologist, psychiatric nurse, psychotherapist and mental health care practice
assistant [31].
Vulnerability markers associated with recurrence of depression
Potential vulnerability markers associated with recurrence focused on sociodemographic char-
acteristics, illness (history) and antidepressant specifications.
Included participant characteristics were age, level of education, having a paid job, parity
and planned pregnancy (yes/no). Level of education was categorized in low (primary/second-
ary education) and higher education.
Included illness (history) determinants were EPDS score around 16 weeks of pregnancy,
number of depressive episodes, number of axis I psychiatric co-morbidities (the sum of both
previous and current diagnoses) as measured with the SCID-I and a history of psychiatric hos-
pital admission.
Antidepressant specifications included duration of antidepressant use, number of previous
tapering attempts, and dose equivalency in early pregnancy. Dose equivalency was calculated
by dividing the prescribed dosage by standard initial dosages, which are: citalopram 20mg,
escitalopram 10mg, fluoxetine 20mg, fluvoxamine 100mg, paroxetine 20mg, sertraline 50mg
and venlafaxine 75mg. Standard dosages were based on American and Dutch pharmaceutical
treatment guidelines [32, 33]. During prospective follow-up, tapering and discontinuation was
reported and divided into three categories: 1) no tapering, 2) intention to taper, but did not
completely discontinue antidepressants during follow-up and 3) participant completely dis-
continued antidepressants at any point during follow-up, whether or not this discontinuation
afterwards persisted throughout follow-up.
Statistical analysis
We performed a case-series study describing individual characteristics of participants. Addi-
tionally, exploratory univariable analyses were used to qualify associations between recurrence
and vulnerability markers (previous section). We used logistic regression analyses with recur-
rence as the outcome variable and the vulnerability markers entered one at a time as indepen-
dent variables. Given the explorative nature of the study the issue of multiple testing is not
relevant in our view. All associations were expressed as odds ratios (OR) with 95% confidence
intervals (95%CI). All statistical analyses were performed with SPSS, version 25.0.
Results
A total of 478 pregnant women were referred for further counselling for both the RCT and the
observational cohort. Thirty-one women (6.5%) were unreachable for counselling, 44 (9.2%)
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decided to participate in the RCT and 248 (51.9%) declined to participate in both trials. Of the
remaining 155 women willing to participate in the observational cohort, another 70 (14.6%)
were excluded for the current study: six had an incomplete baseline record, 49 did not have a
history of depressive disorder, two were currently depressed, three had a miscarriage and ten
were lost to follow-up. This resulted in a total sample of 85 women (Fig 1).
Table 1 illustrates the characteristics of all participants, including those with and without
depression recurrence. Eight women (9.4%) experienced a perinatal recurrence of depression,
none experienced relapse. Overall, mean age was 31.7 years (SD 4.1), 98.8% was of Dutch ori-
gin and 91.5% was living with her partner. Over half of the participants had a high level of edu-
cation and for 50% it was their first pregnancy. Of all 85 women, 44 (51.8%) had one previous
depressive episode and 7.1% had more than 3 episodes. Psychiatric co-morbidity was present
in 71.8% of women (22.4% with current co-morbidity and 67.1% with previous co-morbidity),
with panic disorder and agoraphobia most common (both 24.7% of participants). Overall, the
median duration of antidepressant use was 60 months, during which a limited number of
tapering attempts were undertaken; 81.0% either did not try or only once attempted to discon-
tinue their antidepressants before study participation. During follow-up, 12 women (14.1%)
completely discontinued their medication and four (4.7%) intended to taper medication, but
did not completely discontinue during follow-up.
Women with perinatal recurrence of depression
Out of eight women with a recurrence, six experienced recurrence after childbirth. Three of
the women discontinued antidepressants during follow-up. A visual representation of timing
of onset of recurrence can be seen in Fig 2. Clinical features of individual women are listed in
Table 2 (case numbers correspond with case numbers in Fig 2). The mean age at first onset of
Fig 1. Flowchart of inclusion of participants.
https://doi.org/10.1371/journal.pone.0212964.g001
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depression was 16 years. None of these women had a previous episode with postpartum
onset (for six women this was their first pregnancy). Four women had a positive family his-
tory of psychopathology; case 2 had a father with depression and obsessive-compulsive dis-
order, case 3 a brother with attention-deficit hyperactivity disorder and antidepressant use,
case 7 a cousin who committed suicide and case 8 a mother, aunt and grandma with depres-
sion. All women had two or more psychiatric co-morbidities, mostly anxiety disorders.
Most women received their medication through the general practitioner (GP). Overall,
beliefs about necessity of their medication (BMQ-necessity) was high. However, the women
with the lowest scores were also the women that discontinued their antidepressants during
follow-up. The beliefs about adverse consequences were mild and homogeneous. All
women had a history of (added) non-pharmacological treatment, receiving therapy for mul-
tiple years including cognitive therapy. Three women still received non-pharmacological
therapy in early pregnancy.
All eight women visited the GP on average four times during study follow-up. Women
had several psychiatric healthcare professionals. Five women visited a psychiatrist (mean
number of visits 4.2), four a psychologist (mean number of visits 7.8), four a psychiatric
nurse (mean number of visits 10.8), four a mental health care practice assistant (mean num-
ber of visits 2.0) and two a psychotherapist (mean number of visits 5). Case 7 only visited
her GP (four times in total). The other women visited at least one more healthcare profes-
sional (range 1–5).
During pregnancy, the mean EPDS scores of the eight women remained stable (11.6, 12.1
and 11.1 consecutively), but increased after childbirth, around the time six women had a recur-
rence of depression. Mean EPDS scores around four weeks postpartum were 16.3, and 15.3 at
12 weeks postpartum. Fig 3 shows EPDS scores per case over time.
Table 1. Characteristics of pregnant women with a history of depression, with and without recurrence of depression during the perinatal period.
All (n = 85) Recurrence (n = 8) No recurrence (n = 77) OR (95% CI)
Sociodemographic characteristics
Age, mean (SD) 31.7 (4.1) 30.8 (5.1) 31.8 (4.0) 0.94 (0.78–1.12)
High level of education, yes (%) 51 (65.4) 4 (57.1) 47 (66.2) 0.68 (0.14–3.29)
Paid job, yes (%) 65 (79.3) 6 (75.0) 59 (79.7) 0.76 (0.14–4.17)
Parity, median (range) 1.5 (1–11) 1 (1–5) 2 (1–11) 0.76 (0.38–1.54)
Planned pregnancy, yes (%) 64 (78.0) 7 (87.5) 57 (77.0) 0.48 (0.06–4.17)
Illness (history)
EPDS score around 16 weeks of pregnancy, mean (SD) 6.7 (4.7) 11.6 (4.1) 6.2 (4.4) 1.28 (1.08–1.52)�
No. of depressive episodes, median (range) 1 (1–10) 2.5 (1–6) 1 (1–10) 1.40 (0.94–2.07)
No. of psychiatric co-morbidities, median (range) 1 (0–6) 2.5 (2–4) 1 (0–6) 1.89 (1.16–3.09)�
History of admission to psychiatric institute, yes (%) 12 (14.1) 3 (37.5) 9 (11.7) 4.53 (0.92–22.26)
Antidepressant specifications
Duration of antidepressant use in months, median (range) 60.0 (4–252) 120 (12–228) 48 (4–252) 1.01 (1.00–1.02)�
No. of tapering attempts in history, median (range) 1 (0–6) 0.5 (0–2) 1 (0–6) 0.65 (0.25–1.70)
Dose equivalent at start study, mean (SD) 1.3 (0.6) 1.7 (0.7) 1.3 (0.6) 2.32 (0.84–6.42)
Tapering antidepressants during follow up, n (%) 16 (18.8) 3 (37.5) 13 (16.9) 2.00 (0.89–4.53)
Intention to taper, did not discontinue, n (%) 4 (4.7) 0 (0.0) 4 (5.2)
Discontinued during study, n (%) 12 (14.1) 3 (37.5) 9 (11.7)
Columns may not sum due to missing data.
�p-value < 0.05
https://doi.org/10.1371/journal.pone.0212964.t001
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Vulnerability markers associated with perinatal recurrence of depression
Univariable associations between the independent determinants and recurrence of depression
are presented in Table 1. A higher EPDS score around 16 weeks of pregnancy (OR 1.28, 95%
CI 1.08–1.52), a higher number of psychiatric co-morbidities (OR 1.89, 95%CI 1.16–3.09) and
a longer duration of antidepressant use in months (OR 1.01, 95%CI 1.00–1.02) were associated
with an increased risk of recurrence.
Fig 2. Survival curve of women with recurrence of depression in the perinatal period. Numbers in figure represent separate cases
and match with case numbers listed in Table 2.
https://doi.org/10.1371/journal.pone.0212964.g002
Table 2. Clinical features of women with recurrence of depression in the perinatal period.
Illness characteristics Antidepressant specifications Follow-up
Case
no.


































1 31 1 14 14 1 2 - - GP 17/19 180 2.0 1 - 14
2 32 2 12 28 3 2 + + GP 23/21 120 3.0 1 - 18
3 37 5 17 28 3 3 - + GP 15/15 228 1.0 0 + 3
4 37 1 18 27 6 3 - - Psych 23/16 120 2.0 2 - 22
5 22 1 16 19 2 3 + - Psych 14/18 60 1.5 0 + 26
6 29 1 13 24 3 2 + - GP 21/17 96 1.0 0 - 15
7 32 1 20 27 2 2 - + GP 23/19 120 2.0 0 - 0
8 26 1 18 24 2 4 - + GP 13/18 12 1.0 1 + 15
No. = number, AD = antidepressants, BMQ = beliefs about medicines questionnaire (necessity (nec); score range 5–25, higher score indicates stronger belief in
necessity, adverse (adv); score range 6–30, higher score indicates stronger belief in potential adverse consequences), (-) No/negative, (+) Yes/positive, GP = general
practitioner, Psych = psychiatrist
https://doi.org/10.1371/journal.pone.0212964.t002
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Discussion
In this prospective cohort study, 85 pregnant women with a history of depression and baseline
antidepressant use were assessed for depression recurrence. In total, eight women (9.4%) expe-
rienced a recurrence of depression at follow-up. All women with recurrence had experienced
their first onset of depression during childhood/adolescence and had at least two psychiatric
co-morbidities. Due to the low rate of recurrence, we were only able to explore univariable vul-
nerability markers associated with recurrence. Results yielded associations for recurrence with
depressive symptoms around 16 weeks of pregnancy, number of psychiatric co-morbidities
and duration of antidepressant use.
Two previous observational studies investigated recurrence rates of depression in women
using antidepressant during pregnancy and reported rates ranging from 68 to 16% [23, 24].
Our overall recurrence rate (9.4%) is remarkably lower, despite the longer follow-up period.
Of the women discontinuing, 25% experienced recurrence compared to 7% of the women con-
tinuing. A possible explanation may be the difference in study populations. Cohen et al. [23]
included women through psychiatric institutes and reported that 76.6% had three or more pre-
vious depressive episodes. In the Yonkers study [24], 38% of the women had four or more pre-
vious depressive episodes, compared to 7.1% in our population. Number of previous episodes
in the general population is one of the strongest predictors for recurrence [34]. Another expla-
nation is that both previous studies reported most women had onset of recurrence in the first
trimester [23, 24], whereas in our study, women with onset of recurrence in the first trimester
(at start study) were excluded.
Fig 3. Edinburgh Perinatal Depression Scale (EPDS) sum score in the perinatal period. Each line represents a case
with recurrence of depression. Case numbers match with case numbers listed in Table 2. The horizontal dotted line
represents the EPDS cut-off score.
https://doi.org/10.1371/journal.pone.0212964.g003
Recurrence of depression in the perinatal period
PLOS ONE | https://doi.org/10.1371/journal.pone.0212964 February 22, 2019 8 / 13
During follow-up, 14% of women completely discontinued their medication. This rate
is in accordance with Dutch discontinuation rates during pregnancy as recorded in insur-
ance and pharmacy databases [19, 35]. Similar to Yonkers et al. [24], our exploratory anal-
ysis did not find a significant effect of antidepressant discontinuation on recurrence risk.
Outside of the perinatal period, antidepressants seem to be more protective than placebos
in preventing recurrences, although this effect is not uniform [36] and recent trials have
demonstrated tapering of antidepressants is safe when preventive cognitive therapy is pro-
vided [37, 38].
There were some noticeable details regarding the women with recurrent depression. All
eight women had a first onset of depression during childhood or adolescence, and all but
one of the women had multiple depressive episodes. Age of first onset has been associated
with risk of recurrence, although it is difficult to disentangle the effect of age of first onset
from the number of depressive episodes, as these two are highly correlated [39]. This early-
onset depression has previously been associated with a more severe and chronic course of
depression, often affecting women, with a longer duration of illness, more episodes, higher
symptom severity, more psychiatric co-morbidity and more tendency to attempt suicide
[40, 41].
Number of visits to psychiatric health care professionals during study follow-up ranged
between 0 and 26 in all recurrence cases. Two women did not receive any, or only very limited,
additional psychiatric healthcare, indicating that they did not receive adequate treatment for
their recurrent depressive episode. This is unwanted as a review of 23 longitudinal studies
found that 38% of mothers with postpartum depression (PPD) continued to have major
depression during their child’s first year of life and even beyond, with previous history of
depression as a predictor for a chronic course of PPD [42], affecting the child as well [13]. Ide-
ally, all women would be offered additional care, even before recurrence takes place, as a recent
study among adults showed that adding preventive cognitive therapy to antidepressant treat-
ment resulted in a 41% relative risk reduction of relapse or recurrence of depression compared
with antidepressants alone [37].
The exploratory analyses identified three vulnerability markers associated with recurrence:
Depressive symptoms around 16 weeks of pregnancy, number of psychiatric co-morbidities
and duration of antidepressant use. In early pregnancy, five women already had an EPDS
score above cut-off [28], although they did not fulfil the SCID-I criteria yet for depressive dis-
order. The EPDS consists of ten questions and can thus be easily assessed in early pregnancy.
International clinical guidelines encouraging routine screening for perinatal depression have
been available for over a decade [43]. Previous validation research of the EPDS found that a
cut-off value of 11 in the first trimester, and ten in the second and third trimesters gave the
most adequate combination of sensitivity, specificity, and positive predictive value [28]. Clini-
cians may use these cut-off scores to initiate and monitor additional treatment, to prevent
recurrence and decrease current symptoms of depression. The second marker was number of
psychiatric co-morbidities. Psychiatric co-morbidity has been associated with shorter time to
recurrence in a non-pregnant population [44]. During pregnancy, clinicians should therefore
assess presence of psychiatric co-morbidities, and determine whether additional treatment tar-
geting these co-morbidities is necessary. Lastly, a longer duration of antidepressant use was
associated with recurrence. The OR must be interpreted as an increase of around 1% in the
odds or recurrence per month. Longer antidepressant duration indicates maintenance treat-
ment, which international guidelines recommend for patients with three or more depressive
episodes [45].
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Strengths and limitations
A strength of the current study is that recruitment of participants took place in various settings
(hospitals, midwifery practices, GP’s and social media) and detailed information was gathered
prospectively, thereby preventing recall bias and providing insight into this specific population
across the perinatal period. Moreover, clinical interviews were used to determine (history of)
diagnoses throughout study participation instead of relying on self-report.
However, several limitations should be noted. Due to the inclusion and exclusion criteria,
only women with recurrence of depression after the first trimester were included, limiting our
sample size and thereby potentially the number of recurrences. With these limited numbers,
only exploratory analyses could be conducted, and the possibility of confounding variables
could not be ruled out. Results will have to be replicated in other studies with larger sample
sizes. Other vulnerable groups of women, e.g. women with a history of depressive disorder
who discontinue antidepressants before pregnancy, were not observed. In the Netherlands
approximately 40% of women discontinue antidepressant treatment in the year before preg-
nancy and even higher figures are reported in other countries [19]. In the current study,
women who discontinued antidepressants before pregnancy were excluded. To fully examine
safety of antidepressant discontinuation, future studies should also include women discontinu-
ing antidepressants before pregnancy. Yet, the main aim of the current study deliberately was
to investigate the effects of continuation and discontinuation of antidepressants specifically
during pregnancy. Another limitation is the limited number of women discontinuing their
medication. To specifically examine the effect of discontinuation on recurrence rates, it would
have been preferential to include more women discontinuing antidepressants, for example by
oversampling this group. Lastly, we cannot guarantee generalizability of our results. Out of the
478 women referred for counselling, 248 women declined to participate, without providing a
reason or background information, conforming to common and local ethical procedures. It
remains unknown whether these women would have been eligible for participation and, if so,
whether they would have differed significantly from our current study population. These
women might have differed in their psychiatric history, current symptomatology and treat-
ment management.
Conclusion and future recommendations
The current study presented descriptive data on a prospective cohort of pregnant women with
antidepressant use in early pregnancy and a history of depressive disorder. Three vulnerability
markers associated with recurrence of depression were identified: Depressive symptoms in early
pregnancy, number of current and past psychiatric co-morbidities and duration of antidepres-
sant treatment. Importantly, if future studies can more robustly establish the predictive value of
these vulnerability markers, these markers could easily be assessed as part of routine care proce-
dures by clinicians. Implementing adequate and accessible risk assessment in daily practice can
lead to improved individualized patient-centred care. No effect of discontinuation on risk of
recurrence was observed, however, the proportion of women discontinuing medication was
small and results should therefore be interpreted with caution. Future studies should aim to
define additional predictors for recurrence of depression in pregnancy, assess the effects of
implementing screening instruments during this phase, and to evaluate the effect of treatments
in the perinatal period in order to benefit women and (potentially) their offspring [26, 46].
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